share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K:外国发行人报告
美股sec公告 ·  05/14 14:50
Moomoo AI 已提取核心信息
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The event, which will be held virtually, is set to feature a live webcast of Mr. Drysdale's presentation at 12:40 p.m. ET. Cybin, known for its focus on developing psychedelic-based treatments for mental health conditions, is currently working on CYB003 and CYB004, investigational compounds for major depressive disorder and generalized anxiety disorder, respectively. The company, founded in 2019, operates across multiple countries including Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The webcast will be accessible online and will also be archived on Cybin's investor relations website.
Cybin Inc., a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The event, which will be held virtually, is set to feature a live webcast of Mr. Drysdale's presentation at 12:40 p.m. ET. Cybin, known for its focus on developing psychedelic-based treatments for mental health conditions, is currently working on CYB003 and CYB004, investigational compounds for major depressive disorder and generalized anxiety disorder, respectively. The company, founded in 2019, operates across multiple countries including Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The webcast will be accessible online and will also be archived on Cybin's investor relations website.
处于临床阶段的生物制药公司Cybin Inc. 宣布,其首席执行官道格·德赖斯代尔将于2024年5月21日参加联盟全球合作伙伴医疗保健公司展示会上的炉边谈话。该活动将以虚拟方式举行,将在美国东部时间下午 12:40 通过网络直播德赖斯代尔先生的演讲。Cybin以专注于开发基于迷幻药的心理健康状况疗法而闻名,目前正在研究 CYB003 和 CYB004,这两种药物分别是重度抑郁症和广泛性焦虑症的研究化合物。该公司成立于2019年,业务遍及多个国家,包括加拿大、美国、英国、荷兰和爱尔兰。该网络直播将可在线观看,也将存档在Cybin的投资者关系网站上。
处于临床阶段的生物制药公司Cybin Inc. 宣布,其首席执行官道格·德赖斯代尔将于2024年5月21日参加联盟全球合作伙伴医疗保健公司展示会上的炉边谈话。该活动将以虚拟方式举行,将在美国东部时间下午 12:40 通过网络直播德赖斯代尔先生的演讲。Cybin以专注于开发基于迷幻药的心理健康状况疗法而闻名,目前正在研究 CYB003 和 CYB004,这两种药物分别是重度抑郁症和广泛性焦虑症的研究化合物。该公司成立于2019年,业务遍及多个国家,包括加拿大、美国、英国、荷兰和爱尔兰。该网络直播将可在线观看,也将存档在Cybin的投资者关系网站上。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息